254 related articles for article (PubMed ID: 36877373)
1. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
Shallis RM; Pucar D; Perincheri S; Gore SD; Seropian SE; Podoltsev NA; Zeidan AM
Ann Hematol; 2022 May; 101(5):1145-1147. PubMed ID: 34686913
[No Abstract] [Full Text] [Related]
4. Mediastinal Myeloid Sarcoma with TP53 Mutation Preceding Acute Myeloid Leukemia with a PICALM-MLLT10 Fusion Gene.
Naesens L; Devos H; Nollet F; Michaux L; Selleslag D
Acta Haematol; 2018; 140(2):97-104. PubMed ID: 30227397
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
6. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
7. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
8. Novel treatments for relapsed/refractory acute myeloid leukemia with
Tallis E; Borthakur G
Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
[No Abstract] [Full Text] [Related]
9. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M; Bacher U; Ayuk F; Lebeau A
J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy.
Perl AE; Pratz KW
Cancer J; 2022 Jan-Feb 01; 28(1):14-20. PubMed ID: 35072369
[TBL] [Abstract][Full Text] [Related]
11. The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia.
Zhang Y; Zhang Y; Wang F; Wang M; Liu H; Chen X; Cao P; Ma X; Teng W; Zhang X; Liu H
Cancer Gene Ther; 2020 Feb; 27(1-2):81-88. PubMed ID: 31285539
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.
Peker D; Parekh V; Paluri R; Deal T; Borate U; Di Stasi A; Harada S; Arroyo EA; Reddy V
Int J Hematol; 2014 Nov; 100(5):457-63. PubMed ID: 25209604
[TBL] [Abstract][Full Text] [Related]
13. A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
[TBL] [Abstract][Full Text] [Related]
14. Myeloid sarcoma: An overview.
Ramia de Cap M; Chen W
Semin Diagn Pathol; 2023 May; 40(3):129-139. PubMed ID: 37149396
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
16. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
17. FLT3-targeted treatment for acute myeloid leukemia.
Arai Y; Chi S; Minami Y; Yanada M
Int J Hematol; 2022 Sep; 116(3):351-363. PubMed ID: 35532877
[TBL] [Abstract][Full Text] [Related]
18. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
Grunwald MR; Levis MJ
Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
20. Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.
Gołos A; Góra-Tybor J; Robak T
Expert Opin Investig Drugs; 2023 Jan; 32(1):53-67. PubMed ID: 36669827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
